Wednesday, December 01, 2010

The Golden One

Frazier described the Vioxx case as “the most significant challenge I’ve ever faced,” in a 2004 interview with Bloomberg BusinessWeek.
Merck withdrew the Vioxx painkiller from the market in 2004 when a study showed the drug doubled the risk of heart attacks and strokes. Last month, the company set aside $950 million to resolve a criminal probe, raising potential legal costs from Vioxx to $7.7 billion. Estimates for potential legal costs at the time of the first cases ran as high as $18 billion.

No comments: